Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Stingray Therapeutics is raising $1,500,000.00 in new funding. Sources indicate as part of senior management Chief Business Officer, Scott Jordan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Stingray Therapeutics

Stingray Therapeutics is working on an exciting new effort to fight cancer with 2nd generation immune-oncology agents. Current efforts in this field are the equivalent of trying to do it with one hand of the immune system tied behind its back. At Stingray, we are unleashing the full immune system to take this fight to an entirely new level. The first generation of immune-oncology therapies, checkpoint inhibitors, leverage adaptive immunity to counter cancer’s immunosuppressive checkpoints. However, many patients develop resistance or are non- responsive to treatment given tumors are cold (cancer unrecognized by adaptive immune system).

To learn more about Stingray Therapeutics, visit http://stingraytx.com/

Contact:
Scott Jordan, Chief Business Officer
713-503-7707
https://www.linkedin.com/in/sjordan1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved